Given the “double-edged sword” effects of SHP2 deficiency on chondrogenesis and osteogenesis, caution also must be taken on the skeletal system with the use of SHP2 inhibition67 to treat neoplastic diseases. Here, PTPN11 is linked to neoplasm.